Complex III: Function and Role in Cellular Respiration

Complex III, also called the cytochrome bc1 complex, sits in the inner mitochondrial membrane and acts as a critical relay station in cellular respiration. Its job is to pass electrons from one carrier molecule (ubiquinol) to another (cytochrome c) while using the energy released to push protons across the membrane. That proton movement is ultimately what drives the production of ATP, the cell’s main energy currency. But beyond energy conversion, Complex III has turned out to be involved in oxygen sensing, cell-death signaling, and the generation of reactive oxygen species that serve double duty as both harmful byproducts and essential messengers.

Where Complex III Fits in the Respiratory Chain

Cellular respiration breaks down nutrients in a sequence of steps, and the electron transport chain is the final stretch. Electrons enter the chain at Complexes I and II, carried by molecules derived from the breakdown of sugars and fats. These electrons are then shuttled to Complex III by ubiquinol, a small lipid-soluble molecule that moves freely within the inner mitochondrial membrane. Complex III accepts those electrons and passes them to cytochrome c, a small protein on the outer face of the membrane, which then delivers them to Complex IV. At Complex IV, electrons finally combine with oxygen to form water.

What makes Complex III distinctive is that it does not simply hand electrons off in a straight line. It splits them, sending one electron forward to cytochrome c and routing another back into the membrane’s ubiquinone pool. This splitting is central to how Complex III couples electron movement with proton translocation, and it’s the basis of what biochemists call the Q cycle.

The Q Cycle and Electron Bifurcation

The Q cycle is the mechanism that lets Complex III move protons across the membrane efficiently. When ubiquinol arrives at one binding site (known as the Qo site), it donates two electrons. One of those electrons takes a high-energy path to cytochrome c via an iron-sulfur protein called the Rieske protein. The other takes a low-energy path back to a second binding site (the Qi site) on the opposite side of the membrane, where it reduces a ubiquinone molecule partway. After two rounds of this cycle, the Qi site has received two electrons and picks up two protons from the mitochondrial matrix, regenerating a full ubiquinol molecule. Meanwhile, the protons released at the Qo site are deposited on the intermembrane space side.

This coupling of a thermodynamically favorable reaction (the high-energy electron transfer) with an unfavorable one (the low-energy return path) is a form of electron bifurcation, a concept originally described by Peter Mitchell and now recognized as a fundamental strategy in bioenergetics.¹ The physics of this process involves quantum tunneling of electrons between redox centers within the complex, a phenomenon that has been modeled computationally to understand how both electrons leave the Qo site in a concerted reaction.²

The net result per Q cycle is elegant: for every pair of electrons that enters at the Qo site, four protons end up on the intermembrane-space side of the membrane (two released from ubiquinol oxidation, two consumed from the matrix during ubiquinone reduction at the Qi site). This proton transfer contributes directly to the electrochemical gradient that Complex V (ATP synthase) then uses to make ATP.

Building the Proton Gradient

Complex III does not work in isolation. The entire respiratory chain functions as a coordinated set of proton pumps. Complexes I, III, and IV each use the energy from electron transfer to move protons from the matrix to the intermembrane space, and the cumulative effect is a steep electrochemical gradient across the inner membrane.³ Complex III’s contribution is proportionally significant: the four protons it moves per pair of electrons represent a substantial fraction of the gradient’s total driving force. Structural studies of these respiratory complexes have been central to understanding how electron flow is mechanically linked to proton movement across the membrane.⁴

An important structural detail is that Complex III operates as a dimer: two copies of the complex sit side by side in the membrane. The Rieske iron-sulfur protein physically swings between the Qo site and cytochrome c1 during each catalytic cycle, a conformational change that has been captured in crystal structures of the bacterial version of the complex.⁵ This swinging motion is essential for gating the bifurcated electron flow: if both electrons went to cytochrome c at once, no protons would be moved at the Qi site, and the whole energetic payoff would be lost.

Reactive Oxygen Species and the Cost of Doing Business

The Q cycle’s elegance comes with a risk. The Qo site generates a partially reduced, highly reactive intermediate during ubiquinol oxidation, and if that intermediate hands its electron to oxygen instead of to the Rieske protein, a superoxide radical is born. Along with Complex I, Complex III has been identified as one of the main sources of superoxide and other reactive oxygen species within mitochondria.⁶

At first glance, this looks like pure waste: reactive oxygen species can damage DNA, proteins, and membranes. But cells have turned this leak into a feature. The superoxide produced at the Qo site is released toward the intermembrane space, which means it can escape into the cytoplasm and act as a signaling molecule. The exact mechanism by which the Qo site allows this electron “leak” is still debated, but the functional consequences are becoming clearer.

Oxygen Sensing and Hypoxia Signaling

One of the more surprising discoveries about Complex III is that it plays a central role in how cells detect low oxygen. When oxygen levels drop, the ROS output from Complex III’s Qo site changes in a way that stabilizes a transcription factor called HIF-1α, which then switches on genes involved in adapting to low oxygen: things like building new blood vessels, shifting to anaerobic metabolism, and increasing red blood cell production.⁷

Experiments using cells with genetic defects specifically in the Qo site have shown that this site is required for hypoxic signaling. When the Qo site is disabled, HIF-1α fails to stabilize even under low oxygen conditions, confirming that it is the ROS production at that particular spot in Complex III that triggers the response.⁸ This finding places Complex III at the intersection of energy metabolism and environmental sensing, a dual role that few would have predicted from its original characterization as a simple electron relay.⁹

Supercomplexes and Why Context Matters

Complex III does not float around the inner mitochondrial membrane alone. It frequently associates with Complexes I and IV in larger assemblies called supercomplexes, sometimes nicknamed “respirasomes.” Research over the past two decades has proposed several advantages to this arrangement: it may channel substrates directly between complexes (so ubiquinol or cytochrome c does not have to diffuse far), stabilize individual complexes that might otherwise degrade, and reduce the electron leakage that leads to harmful ROS production.¹⁰

The most common supercomplex in mammalian mitochondria combines one copy of Complex I, a Complex III dimer, and one copy of Complex IV. Whether substrate channeling truly occurs within these structures or whether their main benefit is structural stability is an active area of investigation. Either way, the tight physical association means that disruption of Complex III can destabilize the entire supercomplex, with knock-on effects on electron flow through Complexes I and IV as well.

A key lipid that holds these assemblies together is cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin interacts with and is required for optimal activity of the respiratory chain complexes, including their organization into supercomplexes.¹¹ Diseases that alter cardiolipin composition, such as Barth syndrome, predictably impair Complex III function and supercomplex assembly. Cardiolipin is also involved in mitochondrial apoptosis and membrane dynamics, meaning its connection to Complex III extends well beyond simple structural support.¹²

Assembly and Genetic Diseases

Building a functional Complex III requires coordination between two genomes. The mammalian complex contains about eleven subunits, and only one of them, cytochrome b, is encoded by the mitochondrial genome. All the other subunits, plus several assembly factors, are encoded in the nucleus, synthesized in the cytoplasm, and imported into mitochondria. Early gene discoveries linked to Complex III deficiency included the mitochondrial gene MT-CYB, a nuclear assembly factor called BCS1L, and the nuclear-encoded structural subunit UQCRB. Additional chaperones such as LYRM7/MZM1L have since been identified as necessary for proper Complex III biogenesis.¹³ Another assembly factor, UQCC3, has been shown to be required for cytochrome b stability and overall Complex III activity.¹⁴

Mutations in the cytochrome b gene can cause exercise intolerance, progressive muscle weakness, and sometimes attacks of myoglobinuria (the release of muscle protein into the urine). A study of five patients found multiple different mutations, including nonsense mutations, a missense mutation, and a 24-base-pair deletion, each impairing cytochrome b function. Interestingly, the mutations were not found in tissues other than muscle and showed no maternal inheritance, suggesting they arose as somatic mutations in muscle stem cells after embryonic development.¹⁵

More severe cytochrome b mutations can cause mitochondrial encephalomyopathy, a condition affecting both brain and muscle. One well-documented case involved a stop-codon mutation that deleted the last 215 amino acids of cytochrome b. Muscle fibers carrying high levels of the mutant DNA lost immunoreactivity for the Rieske protein, meaning the entire Complex III structure fell apart when cytochrome b was too badly truncated. Fibers with lower mutation loads maintained some complex integrity.¹⁶

Complex III Inhibitors as Research and Agricultural Tools

Much of what we know about Complex III’s mechanism comes from studying its inhibitors. Antimycin A blocks the Qi site, while myxothiazol blocks the Qo site. Blocking these two sites produces notably different effects. In rat cortical neurons, antimycin A inhibited calcium currents through a hydrogen peroxide-dependent pathway, while myxothiazol increased calcium currents through a superoxide-dependent pathway.¹⁷ Similarly, in coronary artery tissue, both inhibitors reduced vascular contraction, pointing to a role for Complex III-derived ROS in regulating blood vessel tone.¹⁸ The fact that Qi-site and Qo-site inhibition can produce opposite downstream effects underscores how precisely the two halves of the Q cycle are wired into different signaling pathways.

Outside the lab, Complex III inhibitors have major commercial importance. Strobilurin fungicides, widely used in agriculture, work by blocking the Qo site of fungal Complex III and starving the pathogen of ATP. Despite the essential role of ATP throughout fungal development, these fungicides are mostly preventative rather than curative, and several fungal pathogens have developed resistance relatively quickly.¹⁹ Resistance typically arises through point mutations in the cytochrome b gene. Recent work has verified that 24 different point mutations in the soybean pathogen Phytophthora sojae increase resistance to various Complex III inhibitors. Some mutations that confer resistance to one class of inhibitor simultaneously increase sensitivity to a different class, a pattern of negative cross-resistance that could be exploited in designing new fungicides or rotating existing ones.²⁰

Complex III and Programmed Cell Death

Cytochrome c, the small protein that carries electrons from Complex III to Complex IV, has a second life as a trigger for apoptosis (programmed cell death). When cytochrome c is released from the mitochondrial intermembrane space into the cytoplasm, it activates a cascade of enzymes called caspases that dismantle the cell. The release process turns out to require two steps: first, cytochrome c must be freed from cardiolipin, which normally anchors it to the inner membrane; then the outer membrane must be permeabilized by pro-apoptotic proteins like Bax. Neither step alone is enough.²¹

Complex III’s involvement here is indirect but real. In cell-free systems, initiating respiration through substrates feeding Complexes I, II, or III triggered cytochrome c release, but feeding Complex IV directly did not. This pointed to reduction of ubiquinone or activity at Complex III as an essential element in triggering the release.²² Phylogenetic analysis tells the same story from an evolutionary angle: while early cytochrome bc complexes in bacteria simply moved electrons, the mitochondrial version in vertebrates acquired additional roles in triggering apoptosis as organisms became more complex.²³

Complex III in Cancer Metabolism

Cancer cells famously rely on unusual metabolic strategies, and Complex III has emerged as a relevant player. The conventional view is that cancer cells need mitochondrial respiration primarily for ATP. But more recent evidence suggests something different. In tumors lacking their own mitochondrial DNA (and therefore lacking functional respiratory chains), the critical bottleneck is not ATP at all. Instead, it is the ability to run an enzyme called DHODH, which sits in the inner mitochondrial membrane and depends on electron flow through the respiratory chain to synthesize pyrimidines, the building blocks for DNA and RNA. Research using tumor models has demonstrated that this DHODH-driven pyrimidine biosynthesis, rather than ATP production through oxidative phosphorylation, is what makes a working respiratory chain essential for tumor formation.²⁴

Because Complex III is the step that oxidizes ubiquinol back to ubiquinone, it directly regenerates the electron acceptor that DHODH needs. Block Complex III, and ubiquinone stays reduced; DHODH stalls; pyrimidine synthesis slows. This connection has made Complex III inhibitors a subject of interest in oncology research, independent of their established role in agriculture. The challenge is specificity: human and fungal Complex III are similar enough that agricultural Qo-site inhibitors can provide a conceptual starting point, but different enough that drugs safe for human use require significant redesign.

An Ancient Engine With Expanding Responsibilities

Cytochrome bc complexes are among the oldest energy-converting enzymes on Earth. Phylogenomic analysis suggests that a simpler version, the cytochrome b6f complex found today in cyanobacteria and plant chloroplasts, preceded the bc1 form in evolution. The b6f version uses a shorter cytochrome b protein, while the mitochondrial bc1 complex evolved a longer one, presumably to accommodate additional regulatory functions.²³ The core chemistry, bifurcating electrons at a quinol oxidation site, has remained essentially unchanged for billions of years, even as the biological contexts around it have multiplied from bacterial membranes to mitochondria to chloroplasts. That evolutionary conservatism is itself a testament to how well the Q-cycle mechanism works: once nature found this solution, it kept reusing it.